Pipeline Insight: Dyslipidemia - Pipeline agents unlikely to rejuvenate the market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-04-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and eroding the revenues of branded pharmaceuticals.


Scope

  • Analysis of brand drug and franchise erosion following generic incursion across the US and five major European markets
  • Examination of number and frequency of generic competitors entering individual markets
  • Assessment of brand and generic pricing strategies following generic entry
  • In depth case study analysis, utilizing IMS data to examine individual formulation specific brand erosion


    • Report Highlights
    Branded pharmaceuticals face varying levels of generic competition and experience different speeds and severity of erosion depending on the country the drug is marketed in. Manufacturers need to be aware of country specific incentives and barriers to generic prescribing in order to formulate their specific brand defense strategies

    Branded pharmaceuticals also experience different levels of brand erosion depending upon their formulation. Lifecycle management strategies such as producing a range of different formulations can offer protection to branded revenues once the core product patent expires

    Competition within the generics market is becoming increasingly fierce with ever more companies entering the market. Generics manufacturers need to be aware of which branded products and formulations to target in order to receive the greatest return on investment


    Reasons to Purchase

  • Predict the impact of patent expiry on a brand, assisting with brand business planning or generic target identification
  • Assess country specific trends, and how governmental regulations and healthcare provider actions influence brand and generic pricing and prescribing
  • Explore how lifecycle management strategies can protect brand franchises, limiting the impact of generic competition

    • Table of Contents

    Other users found this report page using the following search terms: Dyslipidemia Antidyslipidemia Antidyslipidemic obesity cholesterol dyslipidemia simcor patent pipeline abt335 oceans expiry pitavastatin clinical niacin

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.